The ring plus project: safety and acceptability of vaginal rings that protect women from unintended pregnancy

Céline Schurmans, Irith De Baetselier, Evelyne Kestelyn, Vicky Jespers, Thérèse Delvaux, Stephen K Agaba, Harry van Loen, Joris Menten, Janneke van de Wijgert, Tania Crucitti, RING PLUS study group, Céline Schurmans, Irith De Baetselier, Evelyne Kestelyn, Vicky Jespers, Thérèse Delvaux, Stephen K Agaba, Harry van Loen, Joris Menten, Janneke van de Wijgert, Tania Crucitti, RING PLUS study group

Abstract

Background: Research is ongoing to develop multipurpose vaginal rings to be used continuously for contraception and to prevent Human Immunodeficiency Virus (HIV) infection. Contraceptive vaginal rings (CVRs) are available in a number of countries and are most of the time used intermittently i.e. three weeks out of a 4-week cycle. Efficacy trials with a dapivirine-containing vaginal ring for HIV prevention are ongoing and plans to develop multi-purpose vaginal rings for prevention of both HIV and pregnancy have been elaborated. In contrast with the CVRs, multi-purpose vaginal rings will have to be used continuously. Women who continuously use a CVR will no longer have menses. Furthermore, some safety aspects of CVR use have never been studied in-depth in the past, such as the impact of the vaginal ring on the vaginal microbiota, biofilm formation and induction of inflammation. We studied acceptability and these novel aspects of safety in Rwandan women. Although significant progress has been made over the past decade, Rwanda still has a high unmet need for contraception (with 47% unplanned births) and a generalized HIV epidemic, and CVRs are not yet available.

Methods: We will conduct an open label, single centre, randomized controlled trial. A total of 120 HIV-negative women will be randomized to intermittent CVR use (to allow menstruation) or continuous CVR use. Women will be followed for a maximum of 14 weeks. In parallel, we will conduct a qualitative study using in-depth interview and focus group discussion methodology.

Discussion: In addition to evaluating the safety and acceptability of intermittent and continuous CVR use in Rwandan women, we hope that our findings will inform the development of future multipurpose vaginal rings, will prepare Rwandan study populations for future clinical trials of multipurpose vaginal rings, and will pave the way for introduction of CVRs on African markets.

Trial registration: Clinicaltrials.gov NCT01796613 . Registered 14 February 2013.

Figures

Figure 1
Figure 1
Schedule of the clinical study.
Figure 2
Figure 2
Schedule of assessments.

References

    1. Malcolm RK, Woolfson AD, Toner CF, Morrow RJ, McCullagh SD. Long-term, controlled release of the HIV microbicide TMC120 from silicone elastomer vaginal rings. J Antimicrob Chemother. 2005;56:954–6. doi: 10.1093/jac/dki326.
    1. Malcolm RK, Edwards KL, Kiser P, Romano J, Smith TJ. Advances in microbicide vaginal rings. Antiviral Res. 2010;88(Suppl 1):S30–9. doi: 10.1016/j.antiviral.2010.09.003.
    1. Roumen FJ. Review of the combined contraceptive vaginal ring, NuvaRing. Ther Clin Risk Manag. 2008;4(2):441–51.
    1. Nel A, Smythe S, Young K, Malcolm K, McCoy C, Rosenberg Z, et al. Safety and pharmacokinetics of dapivirine delivery from matrix and reservoir intravaginal rings to HIV-negative women. J Acquir Immune Defic Syndr. 2009;51:416–23. doi: 10.1097/QAI.0b013e3181acb536.
    1. Murphy DJ, Desjardins D, Dereuddre-Bosquet N, Brochard P, Perrot L, Pruvost A, et al. Pre-clinical development of a combination microbicide vaginal ring containing dapivirine and darunavir. J Antimicrob Chemother. 2014;69:2477–88. doi: 10.1093/jac/dku160.
    1. Malcolm RK, Fetherston SM. Delivering on MPTs: addressing the needs, rising to the challenges and making the opportunities. Contraception. 2013;88:321–5. doi: 10.1016/j.contraception.2013.06.009.
    1. Fetherston SM, Boyd P, McCoy CF, McBride MC, Edwards KL, Ampofo S, et al. A silicone elastomer vaginal ring for HIV prevention containing two microbicides with different mechanisms of action. Eur J Pharm Sci. 2013;48:406–15. doi: 10.1016/j.ejps.2012.12.002.
    1. Malcolm RK, Fetherston SM, McCoy CF, Boyd P, Major I. Vaginal rings for delivery of HIV microbicides. Int J Womens Health. 2012;4:595–605. doi: 10.2147/IJWH.S36282.
    1. Barreiros FA, Guazzelli CA, de AF BR, de Araujo FF. Extended regimens of the contraceptive vaginal ring: evaluation of clinical aspects. Contraception. 2010;81(3):223–5. doi: 10.1016/j.contraception.2009.10.007.
    1. Brache V, Faundes A. Contraceptive vaginal rings: a review. Contraception. 2010;82(5):418–27. doi: 10.1016/j.contraception.2010.04.012.
    1. Lopez L, Grimes D, Gallo M, Schulz K. Skin patch and vaginal ring versus combined oral contraceptives for contraception. Cochrane Database of Systematic Reviews 2010, Issue 3 Art No : CD003552 doi:10 1002/14651858 CD003552 pub3 2010.
    1. Merkatz R. Nestorone/Ethinyl Estradiol Contraceptive Vaginal Ring - New User Controlled, Long Acting Contraceptive. Uganda: Research and Best Practices; 2009.
    1. Home » Our Work » IPM Research Studies » IPM Clinical Trials » IPM 011. with poster CROI
    1. van der Straten A, Montgomery ET, Nel A, Cheng H, Wenger L, Young K, et al. High acceptability of a vaginal ring as a microbicide delivery method for HIV prevention in African women. AIDS Behav. 2012;16:1775–86. doi: 10.1007/s10461-012-0215-0.
    1. Home » Our Work » IPM Research Studies » IPM Clinical Trials » The Ring Study. .
    1. Newsroom Backgrounder. ASPIRE – A Study to Prevent Infection with a Ring for Extended Use - Phase III Safety and Effectiveness Study of the Dapivirine Ring. .
    1. Home > Multipurpose Prevention Technologies. .
    1. A comprehensive and flexible conceptual framework for investigating acceptability in microbicide clinical trials (Poster Presentation). C Woodsong, A Simons-Rudolph, P Alleman - Microbicides. Delhi, 2008
    1. Sha BE, Zariffard MR, Wang QJ, Chen HY, Bremer J, Cohen MH, et al. Female genital-tract HIV load correlates inversely with lactobacillus species but positively with bacterial vaginosis and mycoplasma hominis. J Infect Dis. 2005;191(1):25–32. doi: 10.1086/426394.
    1. van de Wijgert JH, Morrison CS, Brown J, Kwok C, Van Der PB, Chipato T, et al. Disentangling contributions of reproductive tract infections to HIV acquisition in African women. Sex Transm Dis. 2009;36(6):357–64. doi: 10.1097/OLQ.0b013e3181a4f695.
    1. Borgdorff H, Tsivtsivadze E, Verhelst R, Marzorati M, Jurriaans S, Ndayisaba GF, et al. Lactobacillus-dominated cervicovaginal microbiota associated with reduced HIV/STI prevalence and genital HIV viral load in African Women. 2014 Sep;8(9):1781-93. doi: 10.1038/ismej.2014.26. Epub 2014 Mar 6.
    1. Kyongo JK, Jespers V, Goovaerts O, Michiels J, Menten J, et al. Searching for lower female genital tract soluble and cellular biomarkers: defining levels and predictors in a cohort of healthy Caucasian women. PLoS One. 2012;7(8):e43951. doi: 10.1371/journal.pone.0043951.
    1. Larsson PG, Brandsborg E, Forsum U, Pendharkar S, Krogh-Andersen K, Nasic S, et al. Extended antimicrobial treatment of bacterial vaginosis combined with human lactobacilli to find the best treatment and minimize the risk of relapses. BMC Infect Dis. 2011;11(1):223. doi: 10.1186/1471-2334-11-223.
    1. Swidsinski A, Dorffel Y, Loening-Baucke V, Schilling J, Mendling W. Response of Gardnerella vaginalis biofilm to 5 days of moxifloxacin treatment. FEMS Immunol Med Microbiol. 2011;61(1):41–6. doi: 10.1111/j.1574-695X.2010.00743.x.
    1. Menard JP, Fenollar F, Henry M, Bretelle F, Raoult D. Molecular quantification of Gardnerella vaginalis and Atopobium vaginae loads to predict bacterial vaginosis. Clin Infect Dis. 2008;47(1):33–43. doi: 10.1086/588661.
    1. Ravel J, Gajer P, Abdo Z, Schneider GM, Koenig SS, McCulle SL, et al. Vaginal microbiome of reproductive-age women. Proc Natl Acad Sci U S A. 2011;108(Suppl 1):4680–7. doi: 10.1073/pnas.1002611107.
    1. Donlan RM. Biofilms and device-associated infections. Emerg Infect Dis. 2001;7(2):277–81. doi: 10.3201/eid0702.010226.
    1. Gunawardana M, Moss JA, Smith TJ, Kennedy S, Kopin E, Nguyen C, et al. Microbial biofilms on the surface of intravaginal rings worn in non-human primates. J Med Microbiol. 2011;60(Pt 6):828–37. doi: 10.1099/jmm.0.028225-0.
    1. Report written by Basinga P , Moore AM, Singh S, Remez L, Nyirazinyoye L. Suggested citation: Basinga P et al., Unintended Pregnancy and Induced Abortion in Rwanda: Causes and Consequences, New York: Guttmacher Institute, 2012. .
    1. Dhont N, Ndayisaba GF, Peltier CA, Nzabonimpa A, Temmerman M, van de Wijgert J. Improved access increases postpartum uptake of contraceptive implants among HIV-positive women in Rwanda. Eur J Contracept Reprod Health Care. 2009;14:420–5. doi: 10.3109/13625180903340584.
    1. Elul B, Delvaux T, Munyana E, Lahuerta M, Horowitz D, Ndagije F, et al. Pregnancy desires, and contraceptive knowledge and use among prevention of mother-to-child transmission clients in Rwanda. AIDS. 2009;23(Suppl 1):S19–26. doi: 10.1097/01.aids.0000363774.91376.dc.
    1. Leslie JA, Munyambanza E, Adamchak SE, Janowitz B, Grey TW, Kirota K. Without strong integration of family planning into PMTCT services in Rwanda, clients remain with a high unmet need for effective family planning. Afr J Reprod Health. 2010;14:144–6.
    1. Morrison CS, Chen PL, Kwok C, Richardson BA, Chipato T, Mugerwa R, et al. Hormonal contraception and HIV acquisition: reanalysis using marginal structural modeling. AIDS. 2010;24:1778–81. doi: 10.1097/QAD.0b013e32833a2537.
    1. Jespers V, Crucitti T, Menten J, Verhelst R, Mwaura M, Mandaliya K, et al. Prevalence and correlates of bacterial vaginosis in different sub-populations of women in sub-Saharan Africa: a cross-sectional study. PLoS One. 2014;9:e109670. doi: 10.1371/journal.pone.0109670.

Source: PubMed

スポンサーと協力者

医学的状態

薬物療法

3
購読する